(hy-DROK-see-yoo-REE-uh)
This page contains brief information about hydroxyurea and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Hydrea
FDA label information for this drug is available at DailyMed.
Use in Cancer
Hydroxyurea is approved to treat:
- Chronic myelogenous leukemia that is refractory (does not respond to treatment).
- Squamous cell carcinoma of the head and neck (excluding the lip) that is locally advanced. It is used with chemoradiation.
The use of hydroxyurea to treat cancer is approved for the Hydrea brand. Hydroxyurea is also approved to treat sickle cell anemia. This use is approved for the Droxia brand.
Hydroxyurea is also being studied in the treatment of other conditions and types of cancer.
More About Hydroxyurea
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Hydroxyurea – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Hydroxyurea – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
